Current status of single-agent phase I trials in Japan: Toward globalization

Journal of Clinical Oncology

Volumn 33, Issue 18, 2015, Pages 2051-2061

  Mizugaki, Hidenori ^a   Yamamoto, Noboru ^a   Fujiwara, Yutaka ^a   Nokihara, Hiroshi ^a   Yamada, Yasuhide ^a   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL STUDY; COMPARATIVE STUDY; DOSE LIMITING TOXICITY; DOSE RESPONSE; EUROPE; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM ADMINISTERED DOSE; MAXIMUM TOLERATED DOSE; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLID TUMOR; STATISTICAL ANALYSIS; TREATMENT RESPONSE; ADOLESCENT; CANCER CENTER; DRUG APPROVAL; INTERNATIONAL COOPERATION; MIDDLE AGED; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG APPROVAL; FEMALE; HUMANS; INTERNATIONALITY; JAPAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937579715     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.4953     Document Type: Article

References (97)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
2. Yonemori K, Hirakawa A, Ando M, et al: The notorious "drug lag" for oncology drugs in Japan. Invest New Drugs 29:706-712, 2011
3. Tsuji K, Tsutani K: Approval of new drugs 1999-2007: Comparison of the US, the EU and Japan situations. J Clin Pharm Ther 35:289-301, 2010
4. Ichimaru K, Toyoshima S, Uyama Y: PMDA's challenge to accelerate clinical development and review of new drugs in Japan. Clin Pharmacol Ther 88:454-457, 2010
5. Yamada K, Yamamoto N, Yamada Y, et al: Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors. Jpn J Clin Oncol 40:404-411, 2010
6. Nyman DW, Campbell KJ, Hersh E, et al: Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23:7785-7793, 2005
7. Asahina H, Tamura Y, Nokihara H, et al: An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 69:1477-1486, 2012
8. Wong CI, Koh TS, Soo R, et al: Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 27:4718-4726, 2009
9. Doi T, Ohtsu A, Tahara M, et al: Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors. Int J Clin Oncol 14:307-314, 2009
10. Weiner LM, Belldegrun AS, Crawford J, et al: Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 14:502-508, 2008
11. Fujisaka Y, Yamada Y, Yamamoto N, et al: Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 66:935-943, 2010
12. Rosen LS, Kurzrock R, Mulay M, et al: Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:2369-2376, 2007
13. Yamamoto N, Tamura T, Yamamoto N, et al: Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 64:1165-1172, 2009
14. Drevs J, Siegert P, Medinger M, et al: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:3045-3054, 2007
15. Yamamoto N, Nokihara H, Yamada Y, et al: A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci 103:504-509, 2012
16. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
17. Asahina H, Nokihara H, Yamamoto N, et al: Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors: A dose-finding phase I study. Invest New Drugs 31:677-684, 2013
18. Naing A, Aghajanian C, Raymond E, et al: Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer 107:1093-1099, 2012
19. Nokihara H, Yamamoto N, Fujiwara Y, et al: Phase I clinical trial investigating maximum tolerated dose, safety and pharmacokinetics of volasertib in Japanese patients with advanced solid tumours. European Cancer Congress, Amsterdam, the Netherlands, September 27-October 1, 2013
20. Schöffski P, Awada A, Dumez H, et al: A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 48:179-186, 2012
21. Shimizu T, Yamamoto N, Yamada Y, et al: Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol 61:751-758, 2008
22. Aghajanian C, Burris HA 3rd, Jones S, et al: Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 25:1082-1088, 2007
23. Nokihara H, Yamamoto N, Yamada Y, et al: A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors. Cancer Chemother Pharmacol 70:559-565, 2012
24. Soria JC, Baselga J, Hanna N, et al: Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. Eur J Cancer 49:1815-1824, 2013
25. Tamura Y, Nokihara H, Yamamoto N, et al: Phase 1 dose escalating study of BMS-754807 in Japanese patients with advanced solid tumors. The 10th Annual Meeting of the Japanese Society of Medical Oncology, Osaka, Japan, July 26-28, 2012
26. Fujisaka Y, Yamada Y, Yamamoto N, et al: A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors. Jpn J Clin Oncol 40:732-738, 2010
27. Raymond E, Alexandre J, Faivre S, et al: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336-2347, 2004
28. Nokihara H, Yamamoto N, Yamada Y, et al: A Phase 1 study evaluating the safety profile and pharmacokinetics of CS1008 (Tigatuzumab), humanized monoclonal antibody targeting death receptor 5 (DR5), in Japanese patients with advanced solid tumours. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Berlin, Germany, November 16-19, 2010
29. Forero-Torres A, Shah J, Wood T, et al: Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 25:13-19, 2010
30. Rowinsky EK, Johnson TR, Geyer CE Jr, et al: DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 18:3151-3163, 2000
31. Boige V, Raymond E, Faivre S, et al: Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer. J Clin Oncol 18:3986-3992, 2000
32. Yamada Y, Yamamoto N, Shimoyama T, et al: Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Cancer Sci 96:721-728, 2005
33. Raymond E, ten Bokkel Huinink WW, Taïeb J, et al: Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J Clin Oncol 20:3508-3521, 2002
34. Yamada K, Yamamoto N, Yamada Y, et al: Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 17:2528-2537, 2011
35. Boss DS, Glen H, Beijnen JH, et al: A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 106:1598-1604, 2012
36. Nokihara H, Yamamoto N, Tamura Y, et al: A Phase 1 Study of necitumumab (anti-EGFR monoclonal antibody) in Japanese patients with advanced solid tumors. The 12th Annual Meeting of the Japanese Society of Medical Oncology, Fukuoka, Japan, July 17-19, 2014
37. Kuenen B, Witteveen PO, Ruijter R, et al: A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 16:1915-1923, 2010
38. Spratlin JL, Cohen RB, Eadens M, et al: Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:780-787, 2010
39. Yamada Y, Tamura T, Yamamoto N, et al: Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors. Cancer Chemother Pharmacol 58:173-182, 2006
40. Hurwitz HI, Cohen RB, McGovren JP, et al: A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol 59:139-147, 2007
41. Kurata T, Tamura T, Sasaki Y, et al: Pharmacokinetic and pharmacodynamic analysis of bisacetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: A phase I study. Jpn J Clin Oncol 30:377-384, 2000
42. McKeage MJ, Raynaud F, Ward J, et al: Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15:2691-2700, 1997
43. Fujisaka Y, Horiike A, Shimizu T, et al: Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors. Jpn J Clin Oncol 36:768-774, 2006
44. Uziely B, Jeffers S, Isacson R, et al: Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785, 1995
45. Yamamoto N, Tamura T, Kamiya Y, et al: Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors. Jpn J Clin Oncol 33:302-308, 2003
46. Fujiwara Y, Yamamoto N, Yamada Y, et al: Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci 100:1728-1734, 2009
47. Kelly WK, O'Connor OA, Krug LM, et al: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931, 2005
48. Tanioka M, Nokihara H, Yamamoto N, et al: Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol 68:505-511, 2011
49. Molckovsky A, Siu LL: First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting. J Hematol Oncol 1:20, 2008
50. Yamamoto N, Nokihara H, Yamada Y, et al: Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 71:1645-1655, 2013
51. Veltkamp SA, Jansen RS, Callies S, et al: Oral administration of gemcitabine in patients with refractory tumors: A clinical and pharmacologic study. Clin Cancer Res 14:3477-3486, 2008
52. Wakui H, Yamamoto N, Kitazono S, et al: A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 74:15-23, 2014
53. Seki Y, Yamamoto N, Tamura Y, et al: Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 69:1099-1105, 2012
54. Mita MM, Mita AC, Chu QS, et al: Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26:361-367, 2008
55. Hartford CM, Desai AA, Janisch L, et al: A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 15:1428-1434, 2009
56. Yamamoto N, Nokihara H, Yasuhide Y, et al: Phase I study of anti-PD-1 antibody ONO-4538 in Japanese patients with advanced solid tumors. The 10th Annual Meeting of the Japanese Society of Medical Oncology, Osaka, Japan, July 26-28, 2012
57. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
58. Horinouchi H, Nakamichi S, Wakui H, et al: Phase IA/IB study of the anti-MET antibody onartuzumab (MetMAb) in patients with solid tumors or MET-positive lung cancer. 15th World Conference on Lung Cancer, Sydney, Australia, October 27-30, 2013
59. Spigel DR, Ervin TJ, Ramlau RA, et al: Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31:4105-4114, 2013
60. Yamamoto N, Yamada Y, Fujiwara Y, et al: Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol 39:260-266, 2009
61. Agus DB, Gordon MS, Taylor C, et al: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534-2543, 2005
62. Yamada Y, Nokihara H, Yamamoto N, et al: Phase I and pharmacokinetics/pharmacodynamics study of a MEK inhibitor RO4987655 in patients with advanced solid tumors. The 12th Annual Meeting of the Japanese Society of Medical Oncology, Fukuoka, Japan, July 17-19, 2014
63. Leijen S, Middleton MR, Tresca P, et al: Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res 18:4794-4805, 2012
64. Yamamoto N, Horiike A, Fujisaka Y, et al: Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 61:489-496, 2008
65. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
66. Honda K, Yamamoto N, Nokihara H, et al: Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 72:577-584, 2013
67. Martinez-Garcia M, Banerji U, Albanell J, et al: First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res 18:4806-4819, 2012
68. Kurata T, Shimada Y, Tamura T, et al: Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors. J Clin Oncol 18:3164-3171, 2000
69. Sessa C, Cuvier C, Caldiera S, et al: Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann Oncol 13:1140-1150, 2002
70. Nemunaitis JJ, Small KA, Kirschmeier P, et al: A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 11:259-263, 2013
71. Yamamoto N, Yasuhide Y, Nokihara H, et al: Phase I dose escalation study of oral bosutinib (SKI-606) in patients with advanced malignant solid tumors. The 7th Annual Meeting of the Japanese Society of Medical Oncology, Nagoya, Japan, March 20-21, 2009
72. Daud AI, Krishnamurthi SS, Saleh MN, et al: Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res 18:1092-1100, 2012
73. O'Donnell A, Padhani A, Hayes C, et al: A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer 93:876-883, 2005
74. Murakami H, Ueda Y, Shimoyama T, et al: Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors. Cancer Chemother Pharmacol 67:1119-1128, 2011
75. Ueda Y, Shimoyama T, Murakami H, et al: Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Cancer Chemother Pharmacol 67:1101-1109, 2011
76. Wakui H, Yamamoto N, Nakamichi S, et al: Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 73:511-516, 2014
77. LoRusso P, Jänne PA, Oliveira M, et al: Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 19:3078-3087, 2013
78. Sausville EA, Arbuck SG, Messmann R, et al: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19:2319-2333, 2001
79. Nokihara H, Yamamoto N, Nakamichi S, et al: A phase 1 study of cabozantinib in Japanese patients with advanced solid tumors: Anti-tumor activity in NSCLC and GIST. The 11th Annual Meeting of the Japanese Society of Medical Oncology, Sendai, Japan, August 29-31, 2013
80. Kurzrock R, Sherman SI, Ball DW, et al: Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660-2666, 2011
81. Murakami H, Tamura T, Yamada Y, et al: ZD0473 pharmacokinetics in Japanese patients: A Phase I dose-escalation study. Eur J Cancer 38:S1-S5, 2002
82. Nakagawa K, Tamura T, Negoro S, et al: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14:922-930, 2003
83. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:2240-2250, 2002
84. Beerepoot LV, Radema SA, Witteveen EO, et al: Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24:1491-1498, 2006
85. Tamura T, Minami H, Yamada Y, et al: A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 1:1002-1009, 2006
86. Holden SN, Eckhardt SG, Basser R, et al: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16:1391-1397, 2005
87. Olmos D, A'Hern RP, Marsoni S, et al: Patient selection for oncology phase I trials: A multi-institutional study of prognostic factors. J Clin Oncol 30:996-1004, 2012
88. Jain RK, Lee JJ, Hong D, et al: Phase I oncology studies: Evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 16:1289-1297, 2010
89. Le Tourneau C, Lee JJ, Siu LL: Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708-720, 2009
90. Le Tourneau C, Stathis A, Vidal L, et al: Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. J Clin Oncol 28:1401-1407, 2010
91. Italiano A, Massard C, Bahleda R, et al: Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 19:787-792, 2008
92. Jain RK, Lee JJ, Ng C, et al: Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol 30:2684-2690, 2012
93. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895-904, 2005
94. Modi S, Panageas KS, Duck ET, et al: Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. J Clin Oncol 20:3665-3673, 2002
95. Pazdur R: Response rates, survival, and chemotherapy trials. J Natl Cancer Inst 92:1552-1553, 2000
96. Lokich J: Tumor response and survival end points in clinical trials: A clinician's perspective. Am J Clin Oncol 27:494-496, 2004
97. Arkenau HT, Barriuso J, Olmos D, et al: Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 27:2692-2696, 2009